Molecules Engineered Against Oncogenic Proteins and Cancer: Discovery, Design, and Development

Molecules Engineered Against Oncogenic Proteins and Cancer is a comprehensive review of the latest molecular advances in cancer treatment, featuring 91 total small molecule kinase/KRAS inhibitors, 80 of which are FDA-approved.

This book provides detailed information on each molecule's structure, function of the kinase target and relevance to cancer, the drug discovery process, and molecular details of drug action.

It also covers mutated protein kinases as oncoproteins and targets for inhibition, along with the details of discovery for each antitumor antikinase agent.

The book is an essential resource for researchers and students in bioscience, medicine, chemistry, and oncology, as well as for those at industrial companies involved in therapeutic discovery.

With a very well-known chemist as the author, Molecules Engineered Against Oncogenic Proteins and Cancer includes information on the discovery process as a whole, effective strategies for innovation, ongoing challenges, and a glimpse of the future of the field.

This book is a must-read for anyone looking to stay up-to-date on the latest advances in cancer treatment.